Jennifer A Frontera,Arjun V Masurkar,Rebecca A Betensky,Zariya Alvarez,Allal Boutajangout,Joshua Chodosh,Salma Hammam,Jessica Hunter,Li Jiang,Melanie Li,Jon Links,Karyn Marsh,Huize Pang,Floyd Silva,Sujata Thawani,Daria Vasilchenko,Alok Vedvyas,Amin Yakubov,Yulin Ge,Thomas Wisniewski
INTRODUCTIONThough brain fog is common in Long-coronavirus disease 2019 (Long-COVID), the incidence of mild cognitive impairment (MCI) is unknown.METHODSIn an observational cohort study, recovered COVID-positive, Long-COVID, and COVID-negative subjects underwent blinded evaluation using National Alzheimer's Coordinating Center (NACC) and National Institute on Aging (NIA) -Alzheimer's Association diagnostic criteria for dementia and MCI. The cumulative incidence of MCI was calculated for each group, and the hazard of MCI was compared between groups.RESULTSAmong 260 subjects, the cumulative incidence of MCI over 4.4 years was higher with Long-COVID (27%) versus recovered-COVID (5%) or COVID-negative status (1%). There was a higher hazard of MCI for patients with Long-COVID compared to those without (hazard ratio [HR] 3.93, 95% confidence interval [CI] 1.86-8.31, p < 0.001), and specifically for the Alzheimer's disease (AD) -related MCI subtype (HR 3.20, 95% confidence interval [CI] 1.14-9.00, p = 0.027).DISCUSSIONThe cumulative incidence and adjusted hazard of MCI (and specifically AD-related MCI) at 4.4 years was significantly higher among Long-COVID patients compared to recovered-COVID and COVID-negative controls.
虽然脑雾在长冠状病毒病2019 (Long-COVID)中很常见,但轻度认知障碍(MCI)的发病率尚不清楚。方法在一项观察性队列研究中,采用美国国家阿尔茨海默病协调中心(NACC)和美国国家老龄化研究所(NIA) -阿尔茨海默病协会痴呆和MCI诊断标准对康复的covid阳性、长covid和covid阴性受试者进行盲法评估。计算各组MCI的累积发病率,并比较各组间MCI的危害。结果在260名受试者中,4.4年MCI累积发病率长covid(27%)高于恢复covid(5%)或covid阴性(1%)。Long-COVID患者发生MCI的风险高于无Long-COVID患者(风险比[HR] 3.93, 95%可信区间[CI] 1.86-8.31, p < 0.001),特别是与阿尔茨海默病(AD)相关的MCI亚型(HR 3.20, 95%可信区间[CI] 1.14-9.00, p = 0.027)。与恢复的covid和covid阴性对照相比,长covid患者4.4年MCI(特别是ad相关MCI)的累积发病率和调整危险度显着更高。
{"title":"Increased incidence of mild cognitive impairment in long COVID patients.","authors":"Jennifer A Frontera,Arjun V Masurkar,Rebecca A Betensky,Zariya Alvarez,Allal Boutajangout,Joshua Chodosh,Salma Hammam,Jessica Hunter,Li Jiang,Melanie Li,Jon Links,Karyn Marsh,Huize Pang,Floyd Silva,Sujata Thawani,Daria Vasilchenko,Alok Vedvyas,Amin Yakubov,Yulin Ge,Thomas Wisniewski","doi":"10.1002/alz.71237","DOIUrl":"https://doi.org/10.1002/alz.71237","url":null,"abstract":"INTRODUCTIONThough brain fog is common in Long-coronavirus disease 2019 (Long-COVID), the incidence of mild cognitive impairment (MCI) is unknown.METHODSIn an observational cohort study, recovered COVID-positive, Long-COVID, and COVID-negative subjects underwent blinded evaluation using National Alzheimer's Coordinating Center (NACC) and National Institute on Aging (NIA) -Alzheimer's Association diagnostic criteria for dementia and MCI. The cumulative incidence of MCI was calculated for each group, and the hazard of MCI was compared between groups.RESULTSAmong 260 subjects, the cumulative incidence of MCI over 4.4 years was higher with Long-COVID (27%) versus recovered-COVID (5%) or COVID-negative status (1%). There was a higher hazard of MCI for patients with Long-COVID compared to those without (hazard ratio [HR] 3.93, 95% confidence interval [CI] 1.86-8.31, p < 0.001), and specifically for the Alzheimer's disease (AD) -related MCI subtype (HR 3.20, 95% confidence interval [CI] 1.14-9.00, p = 0.027).DISCUSSIONThe cumulative incidence and adjusted hazard of MCI (and specifically AD-related MCI) at 4.4 years was significantly higher among Long-COVID patients compared to recovered-COVID and COVID-negative controls.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 1","pages":"e71237"},"PeriodicalIF":14.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Miguel Rosa-Grilo, Dermot Mallon, David L Thomas, Millie Beament, Haroon R Chughtai, Wei Liu, Nicholas Magill, Ian B Malone, Heiko Meyer, Geoff J M Parker, Christina Triantafyllou, Frederik Barkhof, Nick C Fox, Catherine J Mummery
Introduction: Amyloid-targeting therapies for Alzheimer's disease require regular MRI monitoring for amyloid-related imaging abnormalities (ARIA). 3D scans are more sensitive but time intensive; ultra-fast implementations could improve access and reduce burden.
Methods: Eighty scans from 20 participants were acquired with standard 2D fluid-attenuated inversion recovery (FLAIR) and T2*-gradient recalled echo (T2*-GRE), or accelerated Wave-controlled aliasing in parallel imaging (Wave-CAIPI) 3D FLAIR and susceptibility-weighted imaging (SWI) at 3 T. Two neuroradiologists graded ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposits). Bayesian models estimated sensitivity, specificity, severity agreement, and interchangeability between acquisitions.
Results: Accelerated sequences reduced acquisition time by up to 56%. Four participants had ARIA-E and microbleeds; five had microbleeds alone. Sensitivity and specificity for ARIA-E were identical (1.00; 0.94-0.95); severity was comparable. Replacing standard with accelerated FLAIR did not decrease severity agreement (interchangeability 1.4; 95% highest-density interval [HDI] -3.6% to 5.4%). Fast SWI showed higher microbleed severity gradings.
Discussion: Wave-CAIPI offers fast high-resolution FLAIR acquisitions with comparable performance for ARIA-E monitoring. Wave-CAIPI SWI provides high-quality scans that may aid ARIA-H interpretation.
淀粉样蛋白靶向治疗阿尔茨海默病需要定期MRI监测淀粉样蛋白相关成像异常(ARIA)。3D扫描更灵敏,但耗时较长;超高速实现可以改善访问并减轻负担。方法:对20名参与者进行80次扫描,采用标准的2D液体衰减反转恢复(FLAIR)和T2*梯度回忆回声(T2*-GRE),或加速波控混叠并行成像(Wave-CAIPI) 3D FLAIR和敏感性加权成像(SWI),在3 t。两名神经放射学家对ARIA-E(水肿/积液)和ARIA-H(含血黄素沉积)进行分级。贝叶斯模型估计敏感性,特异性,严重性协议和互换性之间的收购。结果:加速序列减少采集时间高达56%。4名参与者有ARIA-E和微出血;其中5例只有微出血。ARIA-E的敏感性和特异性相同(1.00;0.94-0.95);严重程度可比较。用加速FLAIR替代标准并不会降低严重程度一致性(互换性1.4;95%最高密度区间[HDI] -3.6%至5.4%)。快速SWI显示出较高的微出血严重程度等级。讨论:Wave-CAIPI提供快速高分辨率FLAIR采集,具有与ARIA-E监测相当的性能。Wave-CAIPI SWI提供高质量的扫描,可能有助于ARIA-H解释。
{"title":"Accelerated 3D MRI for ARIA monitoring in Alzheimer's disease.","authors":"Miguel Rosa-Grilo, Dermot Mallon, David L Thomas, Millie Beament, Haroon R Chughtai, Wei Liu, Nicholas Magill, Ian B Malone, Heiko Meyer, Geoff J M Parker, Christina Triantafyllou, Frederik Barkhof, Nick C Fox, Catherine J Mummery","doi":"10.1002/alz.71297","DOIUrl":"https://doi.org/10.1002/alz.71297","url":null,"abstract":"<p><strong>Introduction: </strong>Amyloid-targeting therapies for Alzheimer's disease require regular MRI monitoring for amyloid-related imaging abnormalities (ARIA). 3D scans are more sensitive but time intensive; ultra-fast implementations could improve access and reduce burden.</p><p><strong>Methods: </strong>Eighty scans from 20 participants were acquired with standard 2D fluid-attenuated inversion recovery (FLAIR) and T2*-gradient recalled echo (T2*-GRE), or accelerated Wave-controlled aliasing in parallel imaging (Wave-CAIPI) 3D FLAIR and susceptibility-weighted imaging (SWI) at 3 T. Two neuroradiologists graded ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposits). Bayesian models estimated sensitivity, specificity, severity agreement, and interchangeability between acquisitions.</p><p><strong>Results: </strong>Accelerated sequences reduced acquisition time by up to 56%. Four participants had ARIA-E and microbleeds; five had microbleeds alone. Sensitivity and specificity for ARIA-E were identical (1.00; 0.94-0.95); severity was comparable. Replacing standard with accelerated FLAIR did not decrease severity agreement (interchangeability 1.4; 95% highest-density interval [HDI] -3.6% to 5.4%). Fast SWI showed higher microbleed severity gradings.</p><p><strong>Discussion: </strong>Wave-CAIPI offers fast high-resolution FLAIR acquisitions with comparable performance for ARIA-E monitoring. Wave-CAIPI SWI provides high-quality scans that may aid ARIA-H interpretation.</p>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 3","pages":"e71297"},"PeriodicalIF":11.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147508590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuxi Liu, Yanping Li, Yuhan Li, Yu Zhang, Yunhe Wang, Xiao Gu, Yiyang Yue, Jae H Kang, A Heather Eliassen, Eric B Rimm, Molin Wang, Walter C Willett, Frank B Hu, Meir J Stampfer, Dong D Wang
Introduction: Associations of adherence to and changes in Mediterranean (MedDiet) and Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diets with cognitive outcomes are unclear.
Methods: We prospectively followed 86,740 women (Nurses' Health Study, 1980-2023) and 43,500 men (Health Professionals Follow-Up Study, 1986-2023). Diet was assessed repeatedly using food frequency questionnaires. Dementia cases were identified from self-reported physician diagnoses and death records. Cognitive function was assessed by telephone tests, and subjective cognitive decline (SCD) was self-reported.
Results: Participants in the highest versus lowest MedDiet and MIND categories had 21% (hazard ratio [HR] = 0.79, 95% confidence interval [CI]: 0.73-0.84) and 14% (HR = 0.86, 95% CI: 0.81-0.91) lower dementia risk, respectively. Higher adherence was associated with 0.75 to 1.59 fewer years of cognitive aging, and 40% to 42% lower risk of SCD. Similar inverse associations were observed for improved adherence over 4 or 8 years.
Discussion: Adherence to Mediterranean and MIND diets was associated with cognitive benefits.
{"title":"Long-term adherence and changes in the Mediterranean and MIND diets in relation to dementia risk and cognitive function.","authors":"Yuxi Liu, Yanping Li, Yuhan Li, Yu Zhang, Yunhe Wang, Xiao Gu, Yiyang Yue, Jae H Kang, A Heather Eliassen, Eric B Rimm, Molin Wang, Walter C Willett, Frank B Hu, Meir J Stampfer, Dong D Wang","doi":"10.1002/alz.71324","DOIUrl":"https://doi.org/10.1002/alz.71324","url":null,"abstract":"<p><strong>Introduction: </strong>Associations of adherence to and changes in Mediterranean (MedDiet) and Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diets with cognitive outcomes are unclear.</p><p><strong>Methods: </strong>We prospectively followed 86,740 women (Nurses' Health Study, 1980-2023) and 43,500 men (Health Professionals Follow-Up Study, 1986-2023). Diet was assessed repeatedly using food frequency questionnaires. Dementia cases were identified from self-reported physician diagnoses and death records. Cognitive function was assessed by telephone tests, and subjective cognitive decline (SCD) was self-reported.</p><p><strong>Results: </strong>Participants in the highest versus lowest MedDiet and MIND categories had 21% (hazard ratio [HR] = 0.79, 95% confidence interval [CI]: 0.73-0.84) and 14% (HR = 0.86, 95% CI: 0.81-0.91) lower dementia risk, respectively. Higher adherence was associated with 0.75 to 1.59 fewer years of cognitive aging, and 40% to 42% lower risk of SCD. Similar inverse associations were observed for improved adherence over 4 or 8 years.</p><p><strong>Discussion: </strong>Adherence to Mediterranean and MIND diets was associated with cognitive benefits.</p>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 3","pages":"e71324"},"PeriodicalIF":11.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147508656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
INTRODUCTIONThe locus coeruleus (LC), the first region to contain tau pathology in Alzheimer's disease (AD), releases norepinephrine, which has a neuroprotective role. We examined whether LC integrity relates to whole-brain integrity and how AD biomarkers may moderate this relationship.METHODSLC intensity and volume were estimated using automatic segmentation on neuromelanin-sensitive magnetic resonance imaging acquired in n = 71 cognitively unimpaired elderly from the Age-Well randomized controlled trial. We investigated the associations between LC integrity and whole-brain gray matter volume (GMV) and glucose metabolism, as well as the interactions with amyloid positron emission tomography and plasma phosphorylated tau231, neurofilament light chain and glial fibrillary acidic protein.RESULTSWhile only LC intensity was directly associated with GMV, both LC measures (intensity and volume) interacted positively with AD biomarkers to predict GMV and glucose metabolism.DISCUSSIONOur results support concomitant LC and gray matter alterations in the context of aging and elevated AD biomarker levels.CLINICAL TRIAL REGISTRATIONAge-Well randomized clinical trial of the Medit-Ageing European Project.TRIAL REGISTRATION NUMBEREudraCT:2016-002,441-36; IDRCB:2016-A01767-44; ClinicalTrials.gov Identifier: NCT02977819.
{"title":"Altered locus coeruleus links to atrophy and hypometabolism in individuals with high Alzheimer's disease biomarkers.","authors":"Emilie Foyard,Tao Blanchard,Brigitte Landeau,Léa Chauveau,Mikaël Naveau,Géraldine Poisnel,Eric Bui,Gaël Chetelat,Robin de Flores, ","doi":"10.1002/alz.71212","DOIUrl":"https://doi.org/10.1002/alz.71212","url":null,"abstract":"INTRODUCTIONThe locus coeruleus (LC), the first region to contain tau pathology in Alzheimer's disease (AD), releases norepinephrine, which has a neuroprotective role. We examined whether LC integrity relates to whole-brain integrity and how AD biomarkers may moderate this relationship.METHODSLC intensity and volume were estimated using automatic segmentation on neuromelanin-sensitive magnetic resonance imaging acquired in n = 71 cognitively unimpaired elderly from the Age-Well randomized controlled trial. We investigated the associations between LC integrity and whole-brain gray matter volume (GMV) and glucose metabolism, as well as the interactions with amyloid positron emission tomography and plasma phosphorylated tau231, neurofilament light chain and glial fibrillary acidic protein.RESULTSWhile only LC intensity was directly associated with GMV, both LC measures (intensity and volume) interacted positively with AD biomarkers to predict GMV and glucose metabolism.DISCUSSIONOur results support concomitant LC and gray matter alterations in the context of aging and elevated AD biomarker levels.CLINICAL TRIAL REGISTRATIONAge-Well randomized clinical trial of the Medit-Ageing European Project.TRIAL REGISTRATION NUMBEREudraCT:2016-002,441-36; IDRCB:2016-A01767-44; ClinicalTrials.gov Identifier: NCT02977819.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"41 1","pages":"e71212"},"PeriodicalIF":14.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
INTRODUCTIONAir pollution is linked to dementia, but evidence from low-exposure settings is limited. We examined sex-specific associations between long-term exposure to fine particulate matter ≤2.5 µm in diameter (PM2.5) and dementia risk in older adults living in Australia.METHODSIn 16,145 dementia-free Aspirin in Reducing Events in the Elderly (ASPREE) participants (≥70 years; median follow-up 10.3 years), Cox models assessed associations between 1-year mean PM2.5 (continuous and guideline-based categories) and incident dementia, adjusting for demographic, lifestyle, environmental, and genetic factors. Subgroup analyses by sex, apolipoprotein E genotype (APOE), and age were conducted.RESULTSOverall associations were null, but with a trend for increased risk at exposures >10 versus ≤5 µg/m3. In subgroup analyses, positive associations were observed among females, with larger effect estimates at exposure >10 µg/m3, whereas associations remained null among males. No differences were observed across APOE genotypes or age groups.DISCUSSIONFindings suggest a threshold of >10 µg/m3 and heightened susceptibility in females. Further research in low-exposure settings is warranted.
{"title":"The sex-specific association between long-term PM2.5 exposure and incident dementia in community-dwelling older adults in Australia.","authors":"Aoshuang Zhou,Zhen Zhou,Wenhua Yu,Tingting Ye,Alice Owen,Robyn Woods,Suzanne Orchard,Rory Wolfe,Yuming Guo,Joanne Ryan","doi":"10.1002/alz.71256","DOIUrl":"https://doi.org/10.1002/alz.71256","url":null,"abstract":"INTRODUCTIONAir pollution is linked to dementia, but evidence from low-exposure settings is limited. We examined sex-specific associations between long-term exposure to fine particulate matter ≤2.5 µm in diameter (PM2.5) and dementia risk in older adults living in Australia.METHODSIn 16,145 dementia-free Aspirin in Reducing Events in the Elderly (ASPREE) participants (≥70 years; median follow-up 10.3 years), Cox models assessed associations between 1-year mean PM2.5 (continuous and guideline-based categories) and incident dementia, adjusting for demographic, lifestyle, environmental, and genetic factors. Subgroup analyses by sex, apolipoprotein E genotype (APOE), and age were conducted.RESULTSOverall associations were null, but with a trend for increased risk at exposures >10 versus ≤5 µg/m3. In subgroup analyses, positive associations were observed among females, with larger effect estimates at exposure >10 µg/m3, whereas associations remained null among males. No differences were observed across APOE genotypes or age groups.DISCUSSIONFindings suggest a threshold of >10 µg/m3 and heightened susceptibility in females. Further research in low-exposure settings is warranted.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"53 1","pages":"e71256"},"PeriodicalIF":14.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147350359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
INTRODUCTIONAccumulating evidence suggests that amyloid-β (Aβ) preferentially deposits in poorly myelinated cortical regions and may interfere with remyelination. We hypothesized that this vulnerability would manifest as altered Aβ-myelin coupling in preclinical Alzheimer's disease (AD).METHODSWe assessed spatial coupling between amyloid positron emission tomography (PET) and myelin content estimated from T1w/T2w ratio maps in 151 cognitively unimpaired older adults. Associations with preclinical AD, blood-based biomarkers, resting-state functional connectivity (rs-FC), and subjective memory complaints (SMC) were examined.RESULTSCompared with controls, Aβ+ individuals exhibited increased positive and negative Aβ-myelin coupling in late- and early-myelinating regions, respectively, likely reflecting compensatory remyelination versus progressive myelin loss, along with disrupted rs-FC and greater SMC. Serum glial fibrillary acidic protein (GFAP) and plasma phosphorylated tau at threonine 181 (pTau-181) showed differential, region-specific associations with Aβ-myelin coupling, with GFAP partially mediating tau-related effects. Exploratory stratification suggested distinct biomarker profiles linked to the direction of coupling dominance, potentially reflecting different preclinical AD phases.DISCUSSIONAβ-myelin coupling may represent a sensitive, stage-dependent marker of early AD-related cortical pathology.
{"title":"In vivo mapping of cortical amyloid beta-myelin coupling in preclinical Alzheimer's disease.","authors":"Mercedes Atienza,Jose L Cantero","doi":"10.1002/alz.71268","DOIUrl":"https://doi.org/10.1002/alz.71268","url":null,"abstract":"INTRODUCTIONAccumulating evidence suggests that amyloid-β (Aβ) preferentially deposits in poorly myelinated cortical regions and may interfere with remyelination. We hypothesized that this vulnerability would manifest as altered Aβ-myelin coupling in preclinical Alzheimer's disease (AD).METHODSWe assessed spatial coupling between amyloid positron emission tomography (PET) and myelin content estimated from T1w/T2w ratio maps in 151 cognitively unimpaired older adults. Associations with preclinical AD, blood-based biomarkers, resting-state functional connectivity (rs-FC), and subjective memory complaints (SMC) were examined.RESULTSCompared with controls, Aβ+ individuals exhibited increased positive and negative Aβ-myelin coupling in late- and early-myelinating regions, respectively, likely reflecting compensatory remyelination versus progressive myelin loss, along with disrupted rs-FC and greater SMC. Serum glial fibrillary acidic protein (GFAP) and plasma phosphorylated tau at threonine 181 (pTau-181) showed differential, region-specific associations with Aβ-myelin coupling, with GFAP partially mediating tau-related effects. Exploratory stratification suggested distinct biomarker profiles linked to the direction of coupling dominance, potentially reflecting different preclinical AD phases.DISCUSSIONAβ-myelin coupling may represent a sensitive, stage-dependent marker of early AD-related cortical pathology.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"86 1","pages":"e71268"},"PeriodicalIF":14.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147350944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Koral V Wheeler,Victoria R Tennant,Noelle N Lee,Maxwell W Hand,Suchita Ganesan,Patrick Walsh,Meral Tubi,Jamie A Terner,Brandon Hall,Marylan Davison,Arthur W Toga,Sid O'Bryant,Alexandra L Clark,Kristine Yaffe,Meredith N Braskie,
INTRODUCTIONClarifying relationships between amyloid, tau, and cognition is crucial to understanding dementia risk, but has been mainly performed in non-Hispanic White (NHW) participants. It is unknown whether findings are generalizable to other ethnoracial groups.METHODSWe evaluated relationships between amyloid-β (Aβ) positivity, apolipoprotein E allele (APOE) ε4, tau-positron emission tomography (PET) 18F-PI-2620, and cognitive performance in 1181 cognitively unimpaired (451 NHW, 353 Hispanic, and 377 Black) and 383 mild cognitively impaired (85 NHW, 129 Hispanic, and 169 Black) participants from the Health and Aging Brain Study-Health Disparities.RESULTSBlack (β = 0.28, p < 0.001) and Hispanic (β = 0.34, p < 0.001) participants had higher medial temporal lobe (MTL) tau than NHW participants; however, findings were attenuated when accounting for choroid plexus off-target binding. Hispanic participants showed higher tau in lateral temporal regions compared to NHW and Black participants; however, reducing meningeal off-target binding through erosion demonstrated similar lateral temporal tau across groups.DISCUSSIONFactors other than amyloid and tau may impact cognition in Black participants. PI2620 off-target ethnoracial differences should be investigated.
阐明淀粉样蛋白、tau蛋白和认知之间的关系对于理解痴呆风险至关重要,但主要在非西班牙裔白人(NHW)参与者中进行。目前尚不清楚这些发现是否可以推广到其他种族群体。方法我们评估了来自健康与衰老脑研究的1181名认知功能未受损(451名NHW, 353名西班牙裔和377名黑人)和383名轻度认知功能受损(85名NHW, 129名西班牙裔和169名黑人)参与者的淀粉样蛋白-β (Aβ)阳性、载脂蛋白E等位基因(APOE) ε4、tau-正电子发射断层扫描(PET) 18F-PI-2620与认知表现之间的关系。结果黑人(β = 0.28, p < 0.001)和西班牙裔(β = 0.34, p < 0.001)受试者的内侧颞叶(MTL) tau蛋白水平高于黑人(NHW)受试者;然而,当考虑脉络膜丛脱靶结合时,结果减弱。西班牙裔受试者与黑人受试者相比,颞侧区tau蛋白含量较高;然而,通过侵蚀减少脑膜脱靶结合在各组中表现出相似的颞外侧tau。淀粉样蛋白和tau蛋白以外的因素可能影响黑人参与者的认知。应该调查PI2620偏离目标的种族差异。
{"title":"The relationships between ethnoracial identity, Aβ positivity, APOEε4, and medial temporal lobe tau PET.","authors":"Koral V Wheeler,Victoria R Tennant,Noelle N Lee,Maxwell W Hand,Suchita Ganesan,Patrick Walsh,Meral Tubi,Jamie A Terner,Brandon Hall,Marylan Davison,Arthur W Toga,Sid O'Bryant,Alexandra L Clark,Kristine Yaffe,Meredith N Braskie, ","doi":"10.1002/alz.71226","DOIUrl":"https://doi.org/10.1002/alz.71226","url":null,"abstract":"INTRODUCTIONClarifying relationships between amyloid, tau, and cognition is crucial to understanding dementia risk, but has been mainly performed in non-Hispanic White (NHW) participants. It is unknown whether findings are generalizable to other ethnoracial groups.METHODSWe evaluated relationships between amyloid-β (Aβ) positivity, apolipoprotein E allele (APOE) ε4, tau-positron emission tomography (PET) 18F-PI-2620, and cognitive performance in 1181 cognitively unimpaired (451 NHW, 353 Hispanic, and 377 Black) and 383 mild cognitively impaired (85 NHW, 129 Hispanic, and 169 Black) participants from the Health and Aging Brain Study-Health Disparities.RESULTSBlack (β = 0.28, p < 0.001) and Hispanic (β = 0.34, p < 0.001) participants had higher medial temporal lobe (MTL) tau than NHW participants; however, findings were attenuated when accounting for choroid plexus off-target binding. Hispanic participants showed higher tau in lateral temporal regions compared to NHW and Black participants; however, reducing meningeal off-target binding through erosion demonstrated similar lateral temporal tau across groups.DISCUSSIONFactors other than amyloid and tau may impact cognition in Black participants. PI2620 off-target ethnoracial differences should be investigated.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"28 1","pages":"e71226"},"PeriodicalIF":14.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147350946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Caitlin Cheung, Natasha Z Anita, Paola Filigrana, Myriam Fornage, Kevin A Gonzalez, Linda C Gallo, Carmen R Isasi, Robert C Kaplan, Xihao Li, Freddie Márquez, Humberto Parada, Krista M Perreira, Alberto R Ramos, Tatjana Rundek, Wassim Tarraf, Fernando D Testai, Charles DeCarli, Hector M González, Tamar Sofer
Background: Apolipoprotein E (APOE) alleles are well-established genetic risk factors for Alzheimer's disease (AD), but their effects on AD biomarkers (amyloid beta [Aβ]42/40, phosphorylated tau [p-tau]181, neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) may vary across populations due to ancestry-, age-, and sex-related differences. We hypothesized that these effects vary across Hispanic/Latino background groups with distinct ancestral admixture.
Methods: We analyzed ε2 and ε4 allele associations with AD biomarkers using survey-weighted linear regression models, adjusting for demographic covariates. Secondary analyses examined genetic analysis group- and ancestry-specific effects.
Results: ε4 was associated with lower Aβ42/40 and higher p-tau181and GFAP levels, but not with NfL, suggesting its role in Aβ and tau deposition and neuroinflammation. ε4 associations were stronger in those with higher European and lower African ancestry.
Discussion: These findings expand on prior studies suggesting that genetic ancestry modifies APOE-associated AD risk in Hispanic/Latino populations and highlight the importance of capturing ancestry-based heterogeneity in AD biomarker research.
{"title":"APOE and plasma AD biomarkers: The role of genetic ancestry in Hispanics/Latinos.","authors":"Caitlin Cheung, Natasha Z Anita, Paola Filigrana, Myriam Fornage, Kevin A Gonzalez, Linda C Gallo, Carmen R Isasi, Robert C Kaplan, Xihao Li, Freddie Márquez, Humberto Parada, Krista M Perreira, Alberto R Ramos, Tatjana Rundek, Wassim Tarraf, Fernando D Testai, Charles DeCarli, Hector M González, Tamar Sofer","doi":"10.1002/alz.71213","DOIUrl":"10.1002/alz.71213","url":null,"abstract":"<p><strong>Background: </strong>Apolipoprotein E (APOE) alleles are well-established genetic risk factors for Alzheimer's disease (AD), but their effects on AD biomarkers (amyloid beta [Aβ]42/40, phosphorylated tau [p-tau]181, neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) may vary across populations due to ancestry-, age-, and sex-related differences. We hypothesized that these effects vary across Hispanic/Latino background groups with distinct ancestral admixture.</p><p><strong>Methods: </strong>We analyzed ε2 and ε4 allele associations with AD biomarkers using survey-weighted linear regression models, adjusting for demographic covariates. Secondary analyses examined genetic analysis group- and ancestry-specific effects.</p><p><strong>Results: </strong>ε4 was associated with lower Aβ42/40 and higher p-tau181and GFAP levels, but not with NfL, suggesting its role in Aβ and tau deposition and neuroinflammation. ε4 associations were stronger in those with higher European and lower African ancestry.</p><p><strong>Discussion: </strong>These findings expand on prior studies suggesting that genetic ancestry modifies APOE-associated AD risk in Hispanic/Latino populations and highlight the importance of capturing ancestry-based heterogeneity in AD biomarker research.</p>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 3","pages":"e71213"},"PeriodicalIF":11.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147429918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wenjie Fu, Xiaowen Chao, Ying Wang, Shu Liu, Jie Wang, Qi Huang, Ying Luan, Peiyang Luo, Yihui Guan, Yingren Mai, Wei Jia, Qihao Guo, Tianlu Chen, Xiaowei Ma, Fang Xie
Introduction: Alzheimer's disease (AD), a neurodegenerative disease, involves early alterations in the gut microbiota. Bile acids (BAs), which are metabolites produced by the microbiota, may impact brain function through the gut-brain axis.
Methods: By reference to multimodal datasets from the Chinese Preclinical Alzheimer's Disease Study (n = 1397) and the Alzheimer's Disease Neuroimaging Initiative (n = 1275), we analyzed differences in BA levels and their associations with AD biomarkers.
Results: Lithocholic acid (LCA) -family BAs are associated with the amyloid-β status. Longitudinal changes in BA levels correlated with amyloid and tau pathologies. LCA and the deoxycholic acid (DCA) family exhibited predictive value with respect to AD pathology. Imaging transcriptomic analyses suggested that BAs modulated amyloid pathology through multiple mechanisms.
Discussion: DCA- and LCA-family BAs were proposed as molecular bridges that connect age signatures with AD pathology. They represent a new avenue for the development of biomarkers and therapeutic interventions.
{"title":"Bile acids are associated with baseline and longitudinal amyloid and tau pathology in patients with Alzheimer's disease.","authors":"Wenjie Fu, Xiaowen Chao, Ying Wang, Shu Liu, Jie Wang, Qi Huang, Ying Luan, Peiyang Luo, Yihui Guan, Yingren Mai, Wei Jia, Qihao Guo, Tianlu Chen, Xiaowei Ma, Fang Xie","doi":"10.1002/alz.71307","DOIUrl":"https://doi.org/10.1002/alz.71307","url":null,"abstract":"<p><strong>Introduction: </strong>Alzheimer's disease (AD), a neurodegenerative disease, involves early alterations in the gut microbiota. Bile acids (BAs), which are metabolites produced by the microbiota, may impact brain function through the gut-brain axis.</p><p><strong>Methods: </strong>By reference to multimodal datasets from the Chinese Preclinical Alzheimer's Disease Study (n = 1397) and the Alzheimer's Disease Neuroimaging Initiative (n = 1275), we analyzed differences in BA levels and their associations with AD biomarkers.</p><p><strong>Results: </strong>Lithocholic acid (LCA) -family BAs are associated with the amyloid-β status. Longitudinal changes in BA levels correlated with amyloid and tau pathologies. LCA and the deoxycholic acid (DCA) family exhibited predictive value with respect to AD pathology. Imaging transcriptomic analyses suggested that BAs modulated amyloid pathology through multiple mechanisms.</p><p><strong>Discussion: </strong>DCA- and LCA-family BAs were proposed as molecular bridges that connect age signatures with AD pathology. They represent a new avenue for the development of biomarkers and therapeutic interventions.</p>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 3","pages":"e71307"},"PeriodicalIF":11.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jun Pyo Kim, Minku Song, Minyoung Cho, Hyunwoo Lee, Sang-Hyuk Jung, Soohyun Lim, Chanhee Kim, Beomjin Jang, Daeun Shin, Heekyoung Kang, Sohyun Yim, Hyemin Jang, Bo-Hyun Kim, Hee Jin Kim, Duk L Na, Joon-Yong An, Henrik Zetterberg, Kaj Blennow, Fernando Gonzalez-Ortiz, Nicholas J Ashton, Theresa A Day, Sang Won Seo, Hong-Hee Won
Introduction: We aimed to define the genetic architecture and regulatory mechanisms of Alzheimer's disease (AD) -related plasma biomarkers in an East Asian population.
Methods: Genome-wide association studies (GWAS) of plasma phosphorylated tau at threonine 217 (pTau217), pTau181, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were performed in 1,972 individuals from the Korea-Registries to Overcome and Accelerate Dementia Research (K-ROAD) cohort. Results were integrated with Korean single-nucleus transcriptomics, AD-relevant brain quantitative trait loci resources, and summary-based Mendelian randomization (SMR) and colocalization analyses.
Results: Genome-wide significant loci were identified for all biomarkers, including DACT1-DAAM1 (pTau217), KCNJ3 (pTau181), KLHDC4 (NfL), SLC10A7 (GFAP), and PPP4R2 (composite score). Strong associations at the apolipoprotein E locus were observed across biomarkers. Integrative analyses implicated DACT1 as a key regulatory mediator of pTau217, particularly in oligodendrocytes.
Discussion: These findings link ancestry-relevant AD biomarker genetics to brain regulatory mechanisms and support integrative causal analyses.
{"title":"Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies.","authors":"Jun Pyo Kim, Minku Song, Minyoung Cho, Hyunwoo Lee, Sang-Hyuk Jung, Soohyun Lim, Chanhee Kim, Beomjin Jang, Daeun Shin, Heekyoung Kang, Sohyun Yim, Hyemin Jang, Bo-Hyun Kim, Hee Jin Kim, Duk L Na, Joon-Yong An, Henrik Zetterberg, Kaj Blennow, Fernando Gonzalez-Ortiz, Nicholas J Ashton, Theresa A Day, Sang Won Seo, Hong-Hee Won","doi":"10.1002/alz.71275","DOIUrl":"10.1002/alz.71275","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to define the genetic architecture and regulatory mechanisms of Alzheimer's disease (AD) -related plasma biomarkers in an East Asian population.</p><p><strong>Methods: </strong>Genome-wide association studies (GWAS) of plasma phosphorylated tau at threonine 217 (pTau217), pTau181, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were performed in 1,972 individuals from the Korea-Registries to Overcome and Accelerate Dementia Research (K-ROAD) cohort. Results were integrated with Korean single-nucleus transcriptomics, AD-relevant brain quantitative trait loci resources, and summary-based Mendelian randomization (SMR) and colocalization analyses.</p><p><strong>Results: </strong>Genome-wide significant loci were identified for all biomarkers, including DACT1-DAAM1 (pTau217), KCNJ3 (pTau181), KLHDC4 (NfL), SLC10A7 (GFAP), and PPP4R2 (composite score). Strong associations at the apolipoprotein E locus were observed across biomarkers. Integrative analyses implicated DACT1 as a key regulatory mediator of pTau217, particularly in oligodendrocytes.</p><p><strong>Discussion: </strong>These findings link ancestry-relevant AD biomarker genetics to brain regulatory mechanisms and support integrative causal analyses.</p>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 3","pages":"e71275"},"PeriodicalIF":11.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12973132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}